MedTrace Logo

Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

NCT04974983 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2021-07-23

No results posted yet for this study

Summary

This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.

Conditions

Interventions

OTHER

Observation of neurological deficits

Observation of neurological deficits

Sponsors & Collaborators

  • University Hospital Regensburg

    lead OTHER

Eligibility

Min Age
18 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2020-06-30
Completion
2020-08-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974983 on ClinicalTrials.gov